NOTES FROM CONFERNCE ON DUCHENNE MD: Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference Call December 7, 2020 8:30 AM ET Company Participants Doug Ingram – President and Chief Executive Officer Gilmore O’Neill – Executive Vice President, R&D Conference Call Participants Salveen Richter – Goldman Sachs […]